Oxidative stress in end-stage renal disease: An emerging treat to patient outcome

Nephrology Dialysis Transplantation

Volumn 18, Issue 7, 2003, Pages 1272-1280

  Locatelli, Francesco ^a   Canaud, Bernard ^b   Eckardt, Kai Uwe ^c   Stenvinkel, Peter ^d   Wanner, Christoph ^e   Zoccali, Carmine ^f  

^a A MANZONI HOSPITAL   (Italy)

^b LAPEYRONIE HOSPITAL   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f CNR   (Italy)

Author keywords

Anti oxidant therapy; Atherosclerosis; Dialysis complications; Endothelial dysfunction; Inflammation; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIBODY; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CATALASE; DIALYSIS FLUID; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIPID; LOW DENSITY LIPOPROTEIN; OXIDIZING AGENT; PROTEIN; SELENIUM; SUPEROXIDE DISMUTASE;

AGE; AMYLOIDOSIS; ANEMIA; ARTICLE; ASCORBIC ACID DEFICIENCY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL STUDY; DIABETES MELLITUS; DIALYSIS; DIALYSIS MEMBRANE; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ENZYME ANALYSIS; EVIDENCE BASED MEDICINE; HISTOINCOMPATIBILITY; HUMAN; INFLAMMATION; KIDNEY FAILURE; LIPID PEROXIDATION; MALNUTRITION; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PHAGOCYTE; PRIORITY JOURNAL; RISK FACTOR; SELENIUM DEFICIENCY; THREAT; TREATMENT OUTCOME; UREMIA;

EID: 0038353176     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg074     Document Type: Article

References (50)

1. Luke RG. Chronic renal failure - a vasculopathic state. N Engl J Med 1998; 339: 841-843
2. Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 [Suppl 5]: S69-S80
3. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906
4. Brunner FP, Selwood NH on behalf of the EDTA Registry Committee. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992; 42 [Suppl 38]: S4-S15
5. Locatelli F, Manzoni C, Del Vecchio L, Di Filippo S. Changes in the clinical condition of haemodialysis patients. J Nephrol 1999; 12 [Suppl 2]: S82-S91
6. Muntner PM, Coresh J, Klag MJ, Powe NR. Does improved myocardial infarction and stroke survival explain the increase in ESRD incidence? [abstract]. J Am Soc Nephrol 1999; 10: 175
7. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-457
8. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14: 193-199
9. Sies H. Oxidants and antioxidants. Exp Physiol 1997; 82: 291-295
10. Handelman GJ. Evaluation of oxidant stress in dialysis patients. Blood Purif 2000; 18: 343-349
11. Pryor WA. Oxy-radicals and related species: their formation, lifetimes and reactions. Annu Rev Physiol 1986; 48: 657-667
12. Canaud B, Cristol JP, Morena M, Leray-Moragues H, Bosc JY, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 1999; 17: 99-106
13. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
14. Tarng DC, Huang TP, Wei YH et al. 8-Hydroxy-2′-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 934-944
15. Khoa T, Massy ZA, Witko-Sarsat V et al. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Kidney Int 1999; 56: 747-753
16. Nguyen A, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney int 1985; 28: 158-167
17. Descamps-Latscha B, Goldfarb B, Nguyen AT et al. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. Nephron 1991; 59: 279-285
18. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1978-1983
19. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 20-33
20. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786
21. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150: 217-224
22. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218
23. Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998; 54: 580-589
24. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial function via oxidative stress. Effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002-1006
25. Sommerburg O, Grune T, Hampl H et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998; 13: 2583-2587
26. Memon RA, Staprans I, Noor M et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vase Biol 2000; 20: 1536-1542
27. Nguyen-Khoa T, Massy ZA, De Bandt JP et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335-340
28. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966
29. Mezzano D, Pais EO, Aranda E et al. Inflammation, not homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-1850
30. Witko-Sarsat V, Friedlander M, Khoa TN et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
31. Aby-Soud HM, Khassawneh MY, Sohn JT, Murray P, Haxhiu MA, Hazen SL. Peroxidases inhibit nitric oxide (NO)-dependent broncodilation: development of a model describing NO-peroxidase interactions. Biochemistry 2001; 40: 11866-11875
32. Zhang R, Brennan M-L, Fu X et al. Association between myeloperoxidase levels and risk of coronary artery disease. J Am Med Assoc 2001; 286: 2136-2142
33. Pecoitys-Filho R, Stenvinkel P, Marchlewska A et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int in press
34. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. Gamma-tocopherol and its major metabolite, in contrast to alpha tocopherol, inhibit cycloxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA 2000; 97: 11494-11499
35. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr 1985; 115: 807-813
36. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
37. Weiss MF, Erhard P, Kader-Attia FA et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57: 2571-2585
38. Miyata T, Van Ypersele de Strihou C, Kurokowa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999; 55: 389-399
39. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-468
40. Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099
41. Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 2001; 59 [Suppl 78]: S32-S36
42. Zoccali C, Mallamaci F, Asahia K et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 2001; 14: 293-298
43. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62: 301-310
44. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678
45. Laursen JB, Somers M, Kurz S et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282-1288
46. Kielstein JT, Böger RH, Bode-Böger S et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600
47. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
48. Wever R, Boer P, Hijmering M et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19: 1168-1172
49. Brown BG, Zhao XO, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592
50. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995